Workflow
Securities litigation
icon
Search documents
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
Prnewswire· 2025-06-15 14:17
Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm for legal options [1]. - The court-appointed lead plaintiff will represent the interests of the class and any member can move to serve as lead plaintiff [7]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false statements and failing to disclose critical information about the ENVISION clinical study [4]. - Specific allegations include the study's lack of a concurrent control arm, which undermined the ability to demonstrate the drug's effectiveness, and the company's disregard for FDA warnings regarding study design [4]. - As a result of these issues, there was a substantial risk that the new drug application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's prospects [4]. Group 3: Stock Price Impact - Following the FDA's briefing document questioning the effectiveness of UGN-102, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [5]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, the stock price dropped by $3.37, or 44.7%, closing at $4.17 per share on May 21, 2025 [6].
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-06-14 01:00
Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant financial losses for investors [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Rocket securities between February 27, 2025, and May 26, 2025, with a deadline of August 11, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Rocket made positive statements while concealing serious risks, including the occurrence of Serious Adverse Events (SAEs) during clinical trials [3]. Clinical Trial Issues - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which is claimed to have misled investors about the safety of the treatment [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, which included death, following the undisclosed protocol amendment [4]. Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [5].
Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein
GlobeNewswire News Room· 2025-06-11 19:32
Core Viewpoint - A securities class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding its lead product candidate, PGN-EDO51, and its clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit covers all investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to contact the law firm before the lead plaintiff motion deadline of August 8, 2025 [2]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen misrepresented the efficacy and safety of PGN-EDO51, claiming it was less effective than publicly stated [8]. - The CONNECT2 study was described as dangerous or deficient for obtaining FDA approval, undermining the drug's clinical, regulatory, and commercial prospects [8]. - The truth about the drug's performance began to emerge on July 30, 2024, when PepGen reported "positive clinical data" that fell short of expectations, leading to a significant stock price drop of 32.69% [3][4].
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ibotta
Prnewswire· 2025-06-10 13:58
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ibotta, Inc. due to allegations of misleading statements and failure to disclose risks related to its contract with Kroger, which may have led to significant investor losses [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Ibotta to contact them directly to discuss their legal options [1]. - There is a deadline of June 16, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Ibotta [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Financial Performance and Stock Impact - Ibotta conducted its IPO on April 13, 2024, offering 6.6 million shares at a price of $88.00 per share [5]. - On August 13, 2024, Ibotta reported a net loss of $34.0 million for Q2 2024, with operating expenses more than doubling year-over-year, leading to a 26% drop in stock price to $42.66 [6]. - Following a disappointing Q4 earnings report on February 26, 2025, Ibotta's stock plummeted by 46% to close at $34.01 [7]. Group 3: Contractual Risks - The complaint against Ibotta alleges that the company failed to disclose the at-will nature of its contract with Kroger, which could be terminated without warning, posing a significant risk to investors [4]. - Ibotta provided vague warnings about maintaining client relationships without addressing the specific risk of losing a major client like Kroger [4].
COD INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In COC To Contact Him Directly To Discuss Their Options
Prnewswire· 2025-06-10 13:49
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Compass To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]/PRNewswire/ -- Faruqi & ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Vestis Corporation Securities and Sets a Lead Plaintiff Deadline of August 8, 2025
GlobeNewswire News Room· 2025-06-09 20:41
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) between May 2, 2024, to May 6, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Cesar Torres v. Vestis Corporation, et al. (Case No. 1:25-cv-04844) has been commenced in the United States District Court for the Southern District of ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified
Prnewswire· 2025-06-06 13:47
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Compass To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Compass stock or options between May 1, 2024 and May 7, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, June 6, 2025 /PRNewswire/ -- Faruqi ...
Shareholders who lost money on Organon & Co. (NYSE: OGN) Should Contact Wolf Haldenstein
Prnewswire· 2025-06-02 19:59
Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][6]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][6]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly about its quarterly dividend [6]. - The company allegedly misrepresented its commitment to dividends while internally prioritizing debt reduction [6]. - Following the acquisition of Dermavant Sciences Ltd., Organon reduced its quarterly dividend by over 70% [6].
Shareholders who lost money on Krispy Kreme, Inc. (NASDAQ: DNUT) Should Contact Wolf Haldenstein
Prnewswire· 2025-06-02 19:59
Core Viewpoint - A securities class action lawsuit has been filed against Krispy Kreme, alleging false or misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand [1][6]. Allegations - Krispy Kreme allegedly made false or misleading statements and/or failed to disclose a significant decline in demand for products at McDonald's after the initial marketing launch [6]. - This decline led to lower average sales per location [6]. - The partnership with McDonald's was reportedly not profitable [6]. - These issues posed risks to the continuation of the partnership [6]. - As a result, Krispy Kreme would pause expanding to new McDonald's locations [6]. Legal Context - The law firm Wolf Haldenstein, with over 125 years of experience in securities litigation, is representing the investors affected by these alleged misrepresentations [4]. - Investors who purchased Krispy Kreme securities during the specified class period have until July 15, 2025, to request to be appointed as Lead Plaintiff [2].
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Civitas Resources
GlobeNewswire News Room· 2025-06-02 16:18
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Civitas Resources, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's oil production and financial condition [3][5]. Group 1: Allegations Against Civitas - The complaint alleges that Civitas was likely to significantly reduce its oil production in 2025 due to declines following a production peak in the DJ Basin in Q4 2024 and a low TIL count at the end of 2024 [5]. - It is claimed that increasing oil production would necessitate acquiring additional acreage and development locations, leading to significant debt and asset sales to offset acquisition costs [5]. - The company's financial condition reportedly required disruptive cost-reduction measures, including a significant workforce reduction [5]. - As a result, Civitas's business and financial prospects, as well as operational capabilities, were overstated, making public statements materially false and misleading [5]. Group 2: Financial Performance and Market Reaction - On February 24, 2025, Civitas reported its Q4 and full-year financial results, missing consensus estimates in revenue and non-GAAP EPS, and announced a 10% workforce reduction [6]. - Following this news, Civitas's stock price fell by $8.95, or 18.2%, closing at $40.35 per share on February 25, 2025, resulting in investor losses [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses in Civitas are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of July 1, 2025, to seek the role of lead plaintiff in the class action [3][9]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].